BACKGROUND: Male breast cancer (MBC) is a rare disease for which there is limited understanding of treatment patterns and prognostic factors. METHODS: Men with TNM stage I to stage III breast cancer diagnosed between 2004 and 2014 in the National Cancer Data Base were included. Trends in treatment modalities were described using the average annual percentage change (AAPC) and estimated using Joinpoint software for the analysis of trends. Kaplan-Meier curves and the multivariate Cox proportional hazards regression model were used to compare survival between subgroups and to identify prognostic factors. RESULTS: A total of 10,873 MBC cases were included, with a median age at diagnosis of 64 years. Breast-conserving surgery was performed in 24% of patients, and 70% of patients undergoing breast conservation received radiotherapy. Approximately 44% of patients received chemotherapy, and 62% of patients with estrogen receptor-positive disease received endocrine therapy. Oncotype DX was ordered in 35% of patients with lymph node-negative, estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors. During the study period, there was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, radiotherapy after breast conservation, ordering of Oncotype DX, and the use of endocrine therapy (P < .05). On multivariate analysis, factors found to be associated with worse overall survival were older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, and undergoing total mastectomy. Residing in a higher income area; having progesterone receptor-positive tumors; and receipt of chemotherapy, radiotherapy, and endocrine therapy were associated with better overall survival. CONCLUSIONS: Despite the lack of prospective randomized trials in patients with MBC, the results of the current study demonstrated that the treatment of this disease has evolved over the years. These findings further the understanding of the modern treatment and prognosis of MBC, and identify several areas for further research.
BACKGROUND:Male breast cancer (MBC) is a rare disease for which there is limited understanding of treatment patterns and prognostic factors. METHODS:Men with TNM stage I to stage III breast cancer diagnosed between 2004 and 2014 in the National Cancer Data Base were included. Trends in treatment modalities were described using the average annual percentage change (AAPC) and estimated using Joinpoint software for the analysis of trends. Kaplan-Meier curves and the multivariate Cox proportional hazards regression model were used to compare survival between subgroups and to identify prognostic factors. RESULTS: A total of 10,873 MBC cases were included, with a median age at diagnosis of 64 years. Breast-conserving surgery was performed in 24% of patients, and 70% of patients undergoing breast conservation received radiotherapy. Approximately 44% of patients received chemotherapy, and 62% of patients with estrogen receptor-positive disease received endocrine therapy. Oncotype DX was ordered in 35% of patients with lymph node-negative, estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors. During the study period, there was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, radiotherapy after breast conservation, ordering of Oncotype DX, and the use of endocrine therapy (P < .05). On multivariate analysis, factors found to be associated with worse overall survival were older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, and undergoing total mastectomy. Residing in a higher income area; having progesterone receptor-positive tumors; and receipt of chemotherapy, radiotherapy, and endocrine therapy were associated with better overall survival. CONCLUSIONS: Despite the lack of prospective randomized trials in patients with MBC, the results of the current study demonstrated that the treatment of this disease has evolved over the years. These findings further the understanding of the modern treatment and prognosis of MBC, and identify several areas for further research.
Authors: Sharon H Giordano; George H Perkins; Kristine Broglio; Sherry G Garcia; Lavinia P Middleton; Aman U Buzdar; Gabriel N Hortobagyi Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Reshma Jagsi; Paul Abrahamse; Sarah T Hawley; John J Graff; Ann S Hamilton; Steven J Katz Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: Salvatore Piscuoglio; Charlotte K Y Ng; Melissa P Murray; Elena Guerini-Rocco; Luciano G Martelotto; Felipe C Geyer; Francois-Clement Bidard; Samuel Berman; Nicola Fusco; Rita A Sakr; Carey A Eberle; Leticia De Mattos-Arruda; Gabriel S Macedo; Muzaffar Akram; Timour Baslan; James B Hicks; Tari A King; Edi Brogi; Larry Norton; Britta Weigelt; Clifford A Hudis; Jorge S Reis-Filho Journal: Clin Cancer Res Date: 2016-03-09 Impact factor: 12.531
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Kandace P McGuire; Alfredo A Santillan; Paramjeet Kaur; Tammi Meade; Jateen Parbhoo; Morgan Mathias; Corinne Shamehdi; Michelle Davis; Daniel Ramos; Charles E Cox Journal: Ann Surg Oncol Date: 2009-08-04 Impact factor: 5.344
Authors: Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Emma C Fields; Peter DeWitt; Christine M Fisher; Rachel Rabinovitch Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-15 Impact factor: 7.038
Authors: Dejana Braithwaite; Dan H Moore; William A Satariano; Marilyn L Kwan; Robert A Hiatt; Candyce Kroenke; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-09 Impact factor: 4.254
Authors: Mario Campone; Michelino De Laurentiis; Claudio Zamagni; Igor Kudryavcev; Mariëtte Agterof; Ursa Brown-Glaberman; Markéta Palácová; Sanjoy Chatterjee; Lakshmi Menon-Singh; Jiwen Wu; Miguel Martín Journal: Breast Cancer Res Treat Date: 2022-02-25 Impact factor: 4.872
Authors: Mariam F Eskander; Yaming Li; Oindrila Bhattacharyya; Allan Tsung; Bridget A Oppong; Ahmad Hamad; Margaret Gatti-Mays; Samilia Obeng-Gyasi Journal: Breast Cancer Res Treat Date: 2021-08-12 Impact factor: 4.624
Authors: Elizabeth B Elimimian; Leah Elson; Hong Li; Hong Liang; Nadeem Bilani; Emily C Zabor; Abby Statler; Zeina Nahleh Journal: World J Mens Health Date: 2020-12-04 Impact factor: 5.400
Authors: Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik Journal: Breast Cancer Res Treat Date: 2021-04-23 Impact factor: 4.872
Authors: Anne Marie Bak Jylling; Vibeke Jensen; Giedrius Lelkaitis; Peer Christiansen; Sarah Schulz Nielsen; Marianne Djernes Lautrup Journal: Breast Cancer Date: 2020-02-27 Impact factor: 4.239